{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:42:24Z","timestamp":1792510944298,"version":"4.5.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T00:00:00Z","timestamp":1772409600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T00:00:00Z","timestamp":1772409600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Egypt Natl Canc Inst"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Chemotherapy-induced peripheral neuropathy (CIPN) treatment is challenging due to limited and often unsatisfactory therapy options. Scrambler therapy (ST) is gaining interest as treatment option with promising initial results. However, further evaluation is needed to confirm its effectiveness.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>The purpose of this review was to evaluate the efficacy of scrambler therapy in the management of chemotherapy-induced peripheral neuropathy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This systematic review followed the PRISMA guidelines and the Joanna Briggs Institute (JBI) methodology; however, the protocol was not prospectively registered in the PROSPERO database. Electronic databases (CINAHL, Scopus, Web of Science, ScienceDirect, and PubMed) were searched from January 2014 to August 2024. Only English-language randomized controlled trials were eligible. Two reviewers independently screened studies, extracted data, and appraised methodological quality using JBI critical appraisal tools.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Two independent randomized controlled trials, reported across three publications, met the inclusion criteria. The sample size ranged between 35 and 50 participants, and the mean age ranged between 59 and 61 years. The overall quality assessment ranged between low to moderate risk of bias. The reviewed studies demonstrated varying results regarding the efficacy of ST in managing CIPN. Two studies suggest that ST may reduce CIPN symptoms and improve quality of life, although these effects did not reach statistical significance (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&gt;\u20090.05). However, one study\u2019s lack of significant benefit highlights treatment variability and limitations.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Scrambler therapy does not yet meet statistical criteria for a successful treatment CIPN. Further RCTs with large samples, blinding, and extended follow-up is needed to validate ST effectiveness.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s43046-026-00347-w","type":"journal-article","created":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T00:01:16Z","timestamp":1772409676000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy of scrambler therapy in chemotherapy-induced peripheral neuropathy: a systematic review of randomized controlled trials"],"prefix":"10.1186","volume":"38","author":[{"given":"Adnan","family":"Aldawahreh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Etoom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jafar","family":"Alshraideh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muna","family":"Salahat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,2]]},"reference":[{"issue":"4","key":"347_CR1","doi-asserted-by":"publisher","first-page":"2384","DOI":"10.1007\/s13311-021-01142-2","volume":"18","author":"EH Bae","year":"2021","unstructured":"Bae EH, Greenwald MK, Schwartz AG. Chemotherapy-Induced peripheral neuropathy: mechanisms and therapeutic avenues. Neurotherapeutics. 2021;18(4):2384\u201396. https:\/\/doi.org\/10.1007\/s13311-021-01142-2.","journal-title":"Neurotherapeutics"},{"issue":"3","key":"347_CR2","doi-asserted-by":"publisher","first-page":"494","DOI":"10.11124\/JBIES-22-00430","volume":"21","author":"TH Barker","year":"2023","unstructured":"Barker TH, Stone JC, Sears K, Klugar M, Tufanaru C, Leonardi-Bee J, Aromataris E, Munn Z. The revised JBI critical appraisal tool for the assessment of risk of bias for randomized controlled trials. JBI Evid Synthesis. 2023;21(3):494\u2013506. https:\/\/doi.org\/10.11124\/JBIES-22-00430.","journal-title":"JBI Evid Synthesis"},{"issue":"10","key":"347_CR3","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1212\/wnl.0b013e31822cfc59","volume":"77","author":"A Burakgazi","year":"2011","unstructured":"Burakgazi A, Messersmith W, Vaidya D, Hauer P, Hoke A, Polydefkis M. Longitudinal assessment of oxaliplatin-induced neuropathy. Neurology. 2011;77(10):980\u20136. https:\/\/doi.org\/10.1212\/wnl.0b013e31822cfc59.","journal-title":"Neurology"},{"issue":"2","key":"347_CR4","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s40487-021-00168-y","volume":"9","author":"J Burgess","year":"2021","unstructured":"Burgess J, Ferdousi M, Gosal D, Boon C, Matsumoto K, Marshall A, Mak T, Marshall A, Frank B, Malik RA, Alam U. Chemotherapy-Induced peripheral neuropathy: Epidemiology, pathomechanisms and treatment. Oncol Therapy. 2021;9(2):385\u2013450. https:\/\/doi.org\/10.1007\/s40487-021-00168-y.","journal-title":"Oncol Therapy"},{"issue":"6","key":"347_CR5","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1016\/j.jpainsymman.2020.11.025","volume":"61","author":"DS Childs","year":"2021","unstructured":"Childs DS, Le-Rademacher JG, McMurray R, Bendel M, O\u2019Neill C, Smith TJ, Loprinzi CL. Randomized trial of scrambler therapy for Chemotherapy-Induced peripheral neuropathy: crossover analysis. J Pain Symptom Manag. 2021;61(6):1247\u201353. https:\/\/doi.org\/10.1016\/j.jpainsymman.2020.11.025.","journal-title":"J Pain Symptom Manag"},{"key":"347_CR6","doi-asserted-by":"publisher","DOI":"10.1111\/papr.13355","author":"M Chung","year":"2024","unstructured":"Chung M, Chen TH, Wang XS, Kim K, Abdi S. The impact of scrambler therapy on pain and quality of life for chemotherapy-induced peripheral neuropathy: A pilot study. Pain Pract. 2024. https:\/\/doi.org\/10.1111\/papr.13355.","journal-title":"Pain Pract"},{"issue":"5","key":"347_CR7","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s11916-023-01107-4","volume":"27","author":"RS D\u2019Souza","year":"2023","unstructured":"D\u2019Souza RS, Alvarez GaM, Dombovy-Johnson M, Eller J, Abd-Elsayed A. Evidence-Based treatment of pain in Chemotherapy-Induced peripheral neuropathy. Curr Pain Headache Rep. 2023;27(5):99\u2013116. https:\/\/doi.org\/10.1007\/s11916-023-01107-4.","journal-title":"Curr Pain Headache Rep"},{"issue":"1","key":"347_CR8","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1097\/XEB.0000000000000155","volume":"17","author":"Z Jordan","year":"2019","unstructured":"Jordan Z, Lockwood C, Munn Z, Aromataris E. The updated Joanna Briggs Institute model of Evidence-Based healthcare. Int J Evid Based Healthc. 2019;17(1):58\u201371. https:\/\/doi.org\/10.1097\/XEB.0000000000000155.","journal-title":"Int J Evid Based Healthc"},{"issue":"8","key":"347_CR9","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1016\/j.neurom.2022.04.045","volume":"26","author":"J Karri","year":"2023","unstructured":"Karri J, Marathe A, Smith TJ, Wang EJ. The use of scrambler therapy in treating chronic pain syndromes: A systematic review. Neuromodulation Technol Neural Interface. 2023;26(8):1499\u2013509. https:\/\/doi.org\/10.1016\/j.neurom.2022.04.045.","journal-title":"Neuromodulation Technol Neural Interface"},{"issue":"1","key":"347_CR10","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3390\/medsci11010015","volume":"11","author":"N Klafke","year":"2023","unstructured":"Klafke N, Bossert J, Kr\u00f6ger B, Neuberger P, Heyder U, Layer M, Winkler M, Idler C, Kaschdailewitsch E, Heine R, John H, Zielke T, Schmeling B, Joy S, Mertens I, Babadag-Savas B, Kohler S, Mahler C, Witt CM, Steinmann D, Stolz R. Prevention and treatment of Chemotherapy-Induced peripheral neuropathy (CIPN) with Non-Pharmacological interventions: clinical recommendations from a systematic scoping review and an expert consensus Process. Medical sciences (Basel. Switzerland). 2023;11(1):15. https:\/\/doi.org\/10.3390\/medsci11010015.","journal-title":"Switzerland)"},{"issue":"4","key":"347_CR11","first-page":"43","volume":"26","author":"YW Liu","year":"2020","unstructured":"Liu YW, Liu CT, Su YL, Tsai MY. A narrative review of complementary nutritional supplements for Chemotherapy-induced peripheral neuropathy. Altern Ther Health Med. 2020;26(4):43\u20139.","journal-title":"Altern Ther Health Med"},{"issue":"3","key":"347_CR12","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1007\/s00520-019-04881-3","volume":"28","author":"C Loprinzi","year":"2020","unstructured":"Loprinzi C, Le-Rademacher JG, Majithia N, McMurray RP, O\u2019Neill CR, Bendel MA, Beutler A, Lachance DH, Cheville A, Strick DM, Black DF, Tilburt JC, Smith TJ. Scrambler therapy for chemotherapy neuropathy: a randomized phase II pilot trial. Supportive Care Cancer: Official J Multinational Association Supportive Care Cancer. 2020;28(3):1183\u201397. https:\/\/doi.org\/10.1007\/s00520-019-04881-3.","journal-title":"Supportive Care Cancer: Official J Multinational Association Supportive Care Cancer"},{"key":"347_CR13","doi-asserted-by":"publisher","first-page":"153473541984514","DOI":"10.1177\/1534735419845143","volume":"18","author":"G Marineo","year":"2019","unstructured":"Marineo G. Inside the scrambler Therapy, a noninvasive treatment of chronic neuropathic and cancer pain: from the gate control theory to the active principle of information. Integr Cancer Ther. 2019;18:153473541984514. https:\/\/doi.org\/10.1177\/1534735419845143.","journal-title":"Integr Cancer Ther"},{"issue":"1","key":"347_CR14","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s11864-021-00926-0","volume":"23","author":"JN Mezzanotte","year":"2022","unstructured":"Mezzanotte JN, Grimm M, Shinde NV, Nolan T, Worthen-Chaudhari L, Williams NO, Lustberg MB. Updates in the treatment of Chemotherapy-Induced peripheral neuropathy. Curr Treat Options Oncol. 2022;23(1):29\u201342. https:\/\/doi.org\/10.1007\/s11864-021-00926-0.","journal-title":"Curr Treat Options Oncol"},{"issue":"11","key":"347_CR15","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1007\/s11912-023-01449-7","volume":"25","author":"D Molinares","year":"2023","unstructured":"Molinares D, Kurtevski S, Zhu Y. Chemotherapy-Induced peripheral neuropathy: Diagnosis, Agents, general clinical Presentation, and treatments. Curr Oncol Rep. 2023;25(11):1227\u201335. https:\/\/doi.org\/10.1007\/s11912-023-01449-7.","journal-title":"Curr Oncol Rep"},{"issue":"4","key":"347_CR16","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1007\/s00520-014-2424-8","volume":"23","author":"DR Pachman","year":"2014","unstructured":"Pachman DR, Weisbrod BL, Seisler DK, Barton DL, Fee-Schroeder KC, Smith TJ, Lachance DH, Liu H, Shelerud RA, Cheville AL, Loprinzi CL. Pilot evaluation of scrambler therapy for the treatment of chemotherapy-induced peripheral neuropathy. Support Care Cancer. 2014;23(4):943\u201351. https:\/\/doi.org\/10.1007\/s00520-014-2424-8.","journal-title":"Support Care Cancer"},{"key":"347_CR17","doi-asserted-by":"publisher","first-page":"e934475","DOI":"10.12659\/MSM.934475","volume":"27","author":"DV Parums","year":"2021","unstructured":"Parums DV. Editorial: review Articles, systematic reviews, Meta-Analysis, and the updated preferred reporting items for systematic reviews and Meta-Analyses (PRISMA) 2020 guidelines. Med Sci Monitor: Int Med J Experimental Clin Res. 2021;27:e934475. https:\/\/doi.org\/10.12659\/MSM.934475.","journal-title":"Med Sci Monitor: Int Med J Experimental Clin Res"},{"key":"347_CR18","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.jclinepi.2017.07.008","volume":"91","author":"S Polus","year":"2017","unstructured":"Polus S, Pieper D, Burns J, Fretheim A, Ramsay C, Higgins JPT, Mathes T, Pfadenhauer LM, Rehfuess EA. Heterogeneity in application, design, and analysis characteristics was found for controlled before-after and interrupted time series studies included in Cochrane reviews. J Clin Epidemiol. 2017;91:56\u201369. https:\/\/doi.org\/10.1016\/j.jclinepi.2017.07.008.","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"347_CR19","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1177\/0825859719827589","volume":"35","author":"TJ Smith","year":"2020","unstructured":"Smith TJ, Razzak AR, Blackford AL, Ensminger J, Saiki C, Longo-Schoberlein D, Loprinzi CL. A pilot randomized Sham-Controlled trial of MC5-A scrambler therapy in the treatment of chronic Chemotherapy-Induced peripheral neuropathy (CIPN). J Palliat Care. 2020;35(1):53\u20138. https:\/\/doi.org\/10.1177\/0825859719827589.","journal-title":"J Palliat Care"},{"key":"347_CR20","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.ctim.2018.11.022","volume":"42","author":"BY Wu","year":"2019","unstructured":"Wu BY, Liu CT, Su YL, Chen SY, Chen YH, Tsai MY. A review of complementary therapies with medicinal plants for chemotherapy-induced peripheral neuropathy. Complement Ther Med. 2019;42:226\u201332. https:\/\/doi.org\/10.1016\/j.ctim.2018.11.022.","journal-title":"Complement Ther Med"},{"issue":"6","key":"347_CR21","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.3390\/ijms20061451","volume":"20","author":"R Zaj\u0105czkowska","year":"2019","unstructured":"Zaj\u0105czkowska R, Kocot-K\u0119pska M, Leppert W, Wrzosek A, Mika J, Wordliczek J. Mechanisms of Chemotherapy-Induced peripheral neuropathy. Int J Mol Sci. 2019;20(6):1451. https:\/\/doi.org\/10.3390\/ijms20061451.","journal-title":"Int J Mol Sci"},{"key":"347_CR22","doi-asserted-by":"publisher","unstructured":"Wang EJ, Limerick G, D'Souza RS, Lobner K, Williams KA, Cohen, SP, Smith TJ. Safety of Scrambler Therapy: A Systematic Review of Complications and Adverse Effects. Pain medicine (Malden, Mass.). 2023;24(3):325\u201340 https:\/\/doi.org\/10.1093\/pm\/pnac137.","DOI":"10.1093\/pm\/pnac137"}],"container-title":["Journal of the Egyptian National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43046-026-00347-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s43046-026-00347-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43046-026-00347-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T18:29:52Z","timestamp":1781634592000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s43046-026-00347-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,2]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["347"],"URL":"https:\/\/doi.org\/10.1186\/s43046-026-00347-w","relation":{},"ISSN":["2589-0409"],"issn-type":[{"value":"2589-0409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,2]]},"assertion":[{"value":"13 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6"}}